XBiotech Inc. (XBIT): Insider Trading, Congress Trades & Research | Tormere

XBIT

$1.99+7.57%visit website download financials (.py)

XBiotech Inc.

Market Cap

$61M

Live price × shares (2026-10-28)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.79

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Price / TTM revenue

P/B

0.5

Price / stockholders equity

EV/EBITDA

—

TTM

Price Chart

Loading…

Signals

Insider Velocity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Velocity Score

23.98x

Avg Daily Buying (90d)

4,095 sh/day

Baseline Daily Buying

0.0 sh/day

Unique Buyers (90d)

1

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-26	2026-10-28	SIMARD JOHN	Director	Purchase	368.5K	$1.93	$711K	4.19M	View

Recent News

XBiotech (NASDAQ:XBIT) Director John Simard Acquires 368,524 Shares of Company Stock

MarketBeat · 2026-10-28

A co-CEO receives stock options with a $1.85 exercise price from XBiotech (XBIT).

Stock Titan · 2026-10-28

Co-CEO Jan-Paul Simard held no securities before an option grant at XBiotech (XBIT).

Stock Titan · 2026-10-28

XBiotech Inc. Estimates – NASDAQ:XBIT

TradingView · 2026-10-24

XBiotech appoints Jan-Paul Simard as co-CEO By Investing.com

Investing.com UK · 2026-10-23

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

Yahoo · 2026-10-23

XBiotech Appoints Jan-Paul Simard Co-CEO, Effective Oct. 23

Benzinga · 2026-10-23

XBIT Nov 2026 5.000 call (XBIT261120C00005000) stock price, news, quote and history

Yahoo Finance Australia · 2026-10-23

XBIT Nov 2026 2.500 call (XBIT261120C00002500) stock price, news, quote and history

Yahoo Finance UK · 2026-10-20

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

Yahoo · 2026-10-19

XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing Threshold Of 42, More Surviving Patients

Benzinga · 2026-10-19

Xbiotech Inc (XBIT-Q) Stock Price and News

The Globe and Mail · 2026-10-15

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

Yahoo Finance · 2026-06-15

3 Promising Penny Stocks With Market Caps Over $30M

Yahoo Finance · 2025-12-19

November 2025's Promising Penny Stocks To Watch

Yahoo Finance · 2025-11-12

Informational purposes only, not investment advice.